Actively Recruiting
Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion
Led by Groupe Francais De Pneumo-Cancerologie · Updated on 2026-04-29
30
Participants Needed
18
Research Sites
132 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this prospective, interventional study is to evaluate the mechanisms of acquired resistance to amivantamab monotherapy in patients with advanced NSCLC with EGFR ins20. The main question it aims to answer is: What are the mechanisms of acquired resistance to amivantamab monotherapy in this population of patients ? How anticipate the efficacy of subsequent systemic therapies ? After this information session, the participant will be asked to sign the study informed consent. A blood samples (2\*10 mL on ethylenediaminetetraacetic acid (EDTA)) will be taken at time of disease progression and will be sent for central liquid biopsy ctDNA analysis. If available, tumor tissue will also be sent for DNA NGS analysis.
CONDITIONS
Official Title
Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion
Who Can Participate
Eligibility Criteria
You may qualify if you...
- All patients with advanced NSCLC with EGFR exon 20 insertion receiving amivantamab monotherapy in France under ATU or EAP
- Age 18 years or older
- Histologically confirmed advanced NSCLC (metastatic or locally advanced unresectable and not suitable for definitive radiotherapy) with EGFR exon 20 insertion
- Signed informed consent to collect blood samples (liquid biopsy) and tissue biopsy when available at progression on amivantamab
- Confirmed disease progression on amivantamab according to RECIST 1.1
- Enrollment in the French National Health Insurance program or with a third-party payer
You will not qualify if you...
- Receiving amivantamab in combination with another therapy
- Do not consent to liquid biopsy at progression
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 18 locations
1
Oncologie Polyclinique Bordeaux Nord Aquitaine
Bordeaux, France, 33000
Not Yet Recruiting
2
Centre Hospitalier du Morvan
Brest, France, 29200
Actively Recruiting
3
Pneumologie Centre Hospitalier Intercommunal de Créteil
Créteil, France, 94010
Actively Recruiting
4
Oncologie, CLCC Dijon
Dijon, France, 21000
Not Yet Recruiting
5
Pneumologie, CHU Grenoble
Grenoble, France, 38043
Actively Recruiting
6
Pneumologie CH
Le Mans, France, 72000
Not Yet Recruiting
7
Oncologie thoracique Hôpital Nord
Marseille, France, 13915
Actively Recruiting
8
Oncologie, Centre Antoine Lacassagne
Nice, France, 06149
Withdrawn
9
Oncologie Institut Curie
Paris, France, 75005
Not Yet Recruiting
10
Hôpital Cochin
Paris, France, 75014
Actively Recruiting
11
Pneumologie, Hôpital Tenon
Paris, France, 75970
Actively Recruiting
12
Pneumologie Centre Hospitalier
Pau, France, 64000
Not Yet Recruiting
13
Pneumologie CHI Cornouaille
Quimper, France, 02900
Not Yet Recruiting
14
Hôpital Charles Nicolle
Rouen, France, 76031
Actively Recruiting
15
CHU La Réunion Site Nord
Saint-Denis, France, 97411
Actively Recruiting
16
CHU Hôpital Nord
Saint-Etienne, France, 42055
Actively Recruiting
17
CH Bretagne Atlantique
Vannes, France, 56017
Actively Recruiting
18
Pneumologie, Hôpital Mutualiste Resamut
Villeurbanne, France, 69100
Not Yet Recruiting
Research Team
L
Laurent GRELLIER
CONTACT
S
Soizic Ferlandin
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here